Prognostic Models to Predict Survival in Non-Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
Journal of Thoracic Oncology, 08/20/2012
Hoang T et al. – Using the proposed models, the probability of survival with first–line paclitaxel and carboplatin with or without bevacizumab in nonsquamous non–small–cell lung cancer (NSCLC) patients can be estimated. These prognostic models provide a tool for research design and clinical decision making, such as patient stratification and therapy selection.